In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Mural Oncology Plc (MURA – Research Report), with a price target of $18.00.
Andres Y. Maldonado has given his Buy rating due to a combination of factors including the promising outlook for Mural Oncology’s key drug candidate, nemvaleukin, which is involved in several critical trials. The upcoming interim overall survival data from the Phase 3 ARTISTRY-7 study in platinum-resistant ovarian cancer is a significant catalyst, with potential for early success if the hazard ratio meets the required threshold, leading to a Biologics License Application filing in 2025.
Additionally, the Phase 2 ARTISTRY-6 trial in mucosal melanoma is on track to deliver topline results in 2025, targeting a clinically meaningful response rate that could support further regulatory discussions. Historical data and earlier studies suggest strong potential for nemvaleukin, bolstered by its orphan designation. Furthermore, Mural’s exploration of IL-18 and IL-12 assets presents additional upside potential, with innovative strategies aimed at enhancing cytokine therapies, making the stock an attractive investment opportunity.
In another report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $13.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com